WallStreetZenWallStreetZen

NASDAQ: BMRN
Biomarin Pharmaceutical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BMRN

Based on 17 analysts offering 12 month price targets for Biomarin Pharmaceutical Inc

Min Forecast
$60.00+2.55%
Avg Forecast
$91.18+55.83%
Max Forecast
$122.00+108.51%

Should I buy or sell BMRN stock?

Based on 17 analysts offering ratings for Biomarin Pharmaceutical Inc.

Strong Buy
Strong Buy
10 analysts 58.82%
Buy
4 analysts 23.53%
Hold
3 analysts 17.65%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although BMRN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates BMRN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their BMRN stock forecasts and price targets.

BMRN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-21
lockedlocked$00.00+00.00%2026-10-20
lockedlocked$00.00+00.00%2026-10-20
lockedlocked$00.00+00.00%2026-10-15
lockedlocked$00.00+00.00%2026-10-14Find Out Why
HC Wainwright & Co.
Top 19%
82
HoldReiterates$60.00+2.55%2026-09-10
Piper Sandler
Top 14%
87
Strong BuyMaintains$90.00+53.82%2026-09-01Find out why
Jefferies
Top 29%
72
Strong BuyMaintains$105.00+79.46%2026-08-31
BMO Capital
Top 12%
89
BuyInitiates Coverage On$98.00+67.49%2026-08-19
Canaccord Genuity
Top 8%
93
Strong BuyMaintains$114.00+94.84%2026-08-10Find out why

1 of 2

Forecast return on equity

Is BMRN forecast to generate an efficient return?

Company
27.42%
Industry
21.29%
Market
171.95%
BMRN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BMRN forecast to generate an efficient return on assets?

Company
14.79%
Industry
21.83%
BMRN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BMRN earnings per share forecast

What is BMRN's earnings per share in the next 3 years based on estimates from 32 analysts?

Avg 1 year Forecast
$2.37+523.71%
Avg 2 year Forecast
$5.11+1,244.68%
Avg 3 year Forecast
$6.09+1,503%
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

BMRN revenue forecast

What is BMRN's revenue in the next 3 years based on estimates from 32 analysts?

Avg 1 year Forecast
$4.0B+17.13%
Avg 2 year Forecast
$4.6B+34.18%
Avg 3 year Forecast
$5.0B+45.57%
BMRN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BMRN earnings growth forecast

How is BMRN forecast to perform vs Biotechnology companies and vs the US market?

Company
157.05%
Industry
11.65%
Market
32.44%
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BMRN revenue growth forecast

How is BMRN forecast to perform vs Biotechnology companies and vs the US market?

Company
13.63%
Industry
29.74%
Market
12.61%
BMRN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BMRN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BMRN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BMRN$58.51$91.18+55.83%Strong Buy
TECH$72.66$68.33-5.96%Hold
KYMR$126.63$142.73+12.72%Strong Buy
MDGL$430.36$678.80+57.73%Strong Buy
SMMT$16.03$25.61+59.78%Buy
View Top Biotech Stocks

Biomarin Pharmaceutical Stock Forecast FAQ

Is Biomarin Pharmaceutical Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 17 Wall Street analysts covering (NASDAQ: BMRN) stock is to Strong Buy BMRN stock.

Out of 17 analysts, 10 (58.82%) are recommending BMRN as a Strong Buy, 4 (23.53%) are recommending BMRN as a Buy, 3 (17.65%) are recommending BMRN as a Hold, 0 (0%) are recommending BMRN as a Sell, and 0 (0%) are recommending BMRN as a Strong Sell.

If you're new to stock investing, here's how to buy Biomarin Pharmaceutical stock.

What is BMRN's earnings growth forecast for 2026-2028?

(NASDAQ: BMRN) Biomarin Pharmaceutical's forecast annual earnings growth rate of 157.05% is forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and it is also forecast to beat the US market's average forecast earnings growth rate of 32.44%.

Biomarin Pharmaceutical's earnings in 2026 is $72,972,000.On average, 32 Wall Street analysts forecast BMRN's earnings for 2026 to be $458,789,166, with the lowest BMRN earnings forecast at $113,821,370, and the highest BMRN earnings forecast at $754,066,578. On average, 31 Wall Street analysts forecast BMRN's earnings for 2027 to be $989,123,194, with the lowest BMRN earnings forecast at $349,052,202, and the highest BMRN earnings forecast at $1,520,328,303.

In 2028, BMRN is forecast to generate $1,179,135,196 in earnings, with the lowest earnings forecast at $415,448,002 and the highest earnings forecast at $1,737,808,421.

What is BMRN's revenue growth forecast for 2026-2028?

(NASDAQ: BMRN) Biomarin Pharmaceutical's forecast annual revenue growth rate of 13.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.74%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.61%.

Biomarin Pharmaceutical's revenue in 2026 is $3,406,614,000.On average, 32 Wall Street analysts forecast BMRN's revenue for 2026 to be $772,359,298,410, with the lowest BMRN revenue forecast at $733,450,972,851, and the highest BMRN revenue forecast at $819,978,443,124. On average, 31 Wall Street analysts forecast BMRN's revenue for 2027 to be $884,825,652,389, with the lowest BMRN revenue forecast at $801,201,788,501, and the highest BMRN revenue forecast at $957,222,238,255.

In 2028, BMRN is forecast to generate $959,932,270,881 in revenue, with the lowest revenue forecast at $849,208,080,733 and the highest revenue forecast at $1,061,171,346,838.

What is BMRN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: BMRN) forecast ROA is 14.79%, which is lower than the forecast US Biotechnology industry average of 21.83%.

What is BMRN's Price Target?

According to 17 Wall Street analysts that have issued a 1 year BMRN price target, the average BMRN price target is $91.18, with the highest BMRN stock price forecast at $122.00 and the lowest BMRN stock price forecast at $60.00.

On average, Wall Street analysts predict that Biomarin Pharmaceutical's share price could reach $91.18 by Oct 21, 2027. The average Biomarin Pharmaceutical stock price prediction forecasts a potential upside of 55.83% from the current BMRN share price of $58.51.

What is BMRN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: BMRN) Biomarin Pharmaceutical's current Earnings Per Share (EPS) is $0.38. On average, analysts forecast that BMRN's EPS will be $2.37 for 2026, with the lowest EPS forecast at $0.59, and the highest EPS forecast at $3.90. On average, analysts forecast that BMRN's EPS will be $5.11 for 2027, with the lowest EPS forecast at $1.80, and the highest EPS forecast at $7.85. In 2028, BMRN's EPS is forecast to hit $6.09 (min: $2.15, max: $8.98).

What is BMRN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: BMRN) forecast ROE is 27.42%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.